Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
Last trade$0.6892
Day change+$0.0448 (+6.95%)
Day range$0.63 – $0.718
Volume1,409,647
Market cap$43M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$42.99M
Price / earnings
—
Price / book
0.68×
Price / sales
102.84×
EV / sales
97.35×
EV / EBITDA
-1.93×
Profitability
Earnings per share
-$0.28
Return on assets
-27.27%
Return on equity
-29.32%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
15.7×
Quick ratio
14.94×
Cash ratio
0.54×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MBOT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$72K
$241K
$105K
$0
$0
$0
$0
$0
Cost of revenue
$1.1M
$884K
$103K
$0
$0
$0
$0
$0
Gross profit
-$1.02M
-$643K
$2K
$0
$0
$0
$0
$0
Selling, general and administrative
$3.84M
$3.68M
$3.03M
$2.6M
$2.69M
$1.61M
$1.56M
$1.45M
Research and development
$1.63M
$1.86M
$1.29M
$1.54M
$1.17M
$2.11M
$1.46M
$1.98M
Total operating expenses
$5.47M
$5.55M
$4.32M
$4.14M
$3.86M
$3.72M
$3.02M
$3.43M
Operating income
-$6.49M
-$6.19M
-$4.32M
-$4.14M
-$3.86M
-$3.72M
-$3.02M
-$3.43M
Interest expense
$652K
$561K
$649K
$0
$284K
$223K
$104K
$0
Income before taxes
-$5.84M
-$5.63M
-$3.67M
-$3.46M
-$3.58M
-$3.5M
-$2.6M
-$3.39M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.84M
-$5.63M
-$3.67M
-$3.46M
-$3.58M
-$3.5M
-$2.6M
-$3.39M
Net income attributable to common shareholders
-$5.84M
-$5.63M
-$3.67M
-$3.46M
-$3.58M
-$3.5M
-$2.6M
-$3.39M
EBITDA
-$6.47M
-$6.17M
-$4.31M
-$4.13M
-$3.85M
-$3.71M
-$3.01M
-$3.4M
Basic earnings per share
-$0.09
-$0.08
-$0.05
-$0.05
-$0.07
-$0.10
-$0.08
-$0.20
Diluted earnings per share
-$0.09
-$0.08
-$0.05
-$0.05
-$0.07
-$0.10
-$0.08
-$0.20
Recent news
Company coverage with links to the original publishers.
Microbot Medical reported a Q3 loss of $0.09 per share, missing the consensus estimate of $0.08 loss by 12.5%. The company posted revenues of $0.07 million, missing estimates by 71.2%. The stock has declined 48.5% year-to-date and received a Zacks Rank #4 (Sell) rating with unfavorable estimate revisions.
Microbot Medical (NASDAQ: MBOT) announced expansion of its LIBERTY robotic system across the U.S., securing its first California customer and expanding into North Carolina. The company is on track to establish 12 sales territories by year-end, hired additional sales leadership, and expects positive gross margins in 2027 through manufacturing efficiencies. International expansion into Asia and Middle East is in advanced stages with CE mark approval expected in late Q4 2026 or early Q1 2027.
The healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Health; Senseonics demonstrated strong real-world data for its year-long continuous glucose monitor; Microbot Medical achieved clinical milestones with its robotic endovascular system; LivaNova received FDA approval for its sleep apnea treatment device; and Clover Health showed AI-assisted primary care reduces hospitalizations in high-risk patients.
Microbot Medical announced that its operations in the USA and Israel remain unaffected by current geopolitical events. The company is proceeding with its commercial expansion of the LIBERTY Endovascular Robotic System, including hiring additional sales representatives and a Director of HEOR. The company plans a full market release at the Society of Interventional Radiology conference in April 2026 and maintains sufficient U.S. inventory to support current and anticipated demand.
Microbot Medical completed a three-tranche preferred investment option exercise, raising approximately $29.2 million in gross proceeds, with potential additional proceeds of $63 million from future option exercises.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.